Navigation Links
Golden Meditech as First Chinese Healthcare Enterprise to Obtain Approval for Taiwan Depositary Receipts Offering
Date:1/3/2011

HONG KONG, Jan. 3, 2011 /PRNewswire-Asia-FirstCall/ -- Golden Meditech Holdings Limited ("Golden Meditech" or the "Company," together with its subsidiary collectively as the "Group" - 801.HK), Mainland China's leading integrated healthcare enterprise, is pleased to announce that the Company has obtained the approvals from the Taiwan Stock Exchange and the Taiwan Securities and Futures Bureau for its proposed offering and listing of Taiwan Depositary Receipts ("TDR") on the Taiwan Stock Exchange.  The Company will become the first Mainland Chinese healthcare enterprise to list its TDR on the Taiwan Stock Exchange.

The Company intends to offer 90 million TDR units (equivalent to 180 million ordinary Shares of the Company).  A portion of the proceeds will fund the establishment of a representative office in Taiwan.  In view of the rare opportunities arising from the Economic Cooperation Framework Agreement ("ECFA") so as to foster closer ties between industry counterparts on both sides of the Taiwan Strait, the Company is actively pursuing to strengthen its core businesses and market presence through Taiwan's talent advantage.  

According to the Company's recently published interim results in accordance with Hong Kong Accounting Standards, the Group's revenue for the six month ended September 30th, 2010 amounted to HK$163 million with 24% growth relative to the previous corresponding period.  Profit for the period amounted to HK$161 million with 170% growth relative to the previous interim reporting period.

Mr. Kam Yuen, the Company's Chairman and Chief Executive Officer pointed out that the rapid growth of the Group's hospital management business, the penetration of the Autologous Blood Recovery Systems into mid-tier hospitals and the substantial growth in medical accessories consumption all contributed to the increase in the Group's revenue for the period.  The hospital management business accounted for 23% of the Group's total revenue at HK$38million.

About Golden Meditech Holdings Limited

Golden Meditech Holdings Limited is China's leading integrated-healthcare device and service operator, and the first medical device enterprise that was publicly listed outside of the PRC on the Stock Exchange of Hong Kong Limited (HKEx).  Golden Meditech is a first-mover in China, having established dominant positions in medical devices and healthcare services markets over the years, thanks to its strengths in innovation and market expertise and the ability to capture emerging market opportunities.  Going forward, the Group will continue to pursue a leading position in China's healthcare industry both through organic growth and strategic expansion.

For enquiries, please contact:

Investor Relations Department

Golden Meditech Holdings Limited

Address:

48/F, Bank of China Tower, 1 Garden Road, Central, Hong Kong

Tel: +852-3605-8180

Fax: +852-3605-8181

Email: ir@goldenmeditech.com

Website: www.goldenmeditech.com


'/>"/>
SOURCE Golding Meditech Holdings Limited
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Golden Meditech Announces Annual Results for FY 2009/10
2. Golden Meditech Announces Plan to Issue Taiwan Depository Receipts
3. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
4. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
5. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
6. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
7. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
8. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
9. Tainted Chinese Food Ingredients First Discovered in 2005
10. First Patient Enrolled in Europe in Ovature Phase III Ovarian Cancer Trial
11. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... 2016   CytoSorbents Corporation (NASDAQ: CTSO ... Union approved CytoSorb ® cytokine adsorber to treat ... announced that Dr. Phillip Chan , Chief Executive ... Micro Main Event investor conference held from December ... Sunset Boulevard Hotel in Los Angeles, California ...
(Date:12/2/2016)... 2016 On Thursday, the NASDAQ Composite ... Jones Industrial Average edged 0.36% higher, to finish at 19,191.93; ... were broad based as six out of nine sectors ended ... on the following Services equities: Myriad Genetics Inc. (NASDAQ: ... INC Research Holdings Inc. (NASDAQ: INCR ), and ...
(Date:12/2/2016)... Dec. 1, 2016 The concept of rare diseases ... given to this sector has been taking shape in ... the political aspects and initiatives related to orphan medicinal products ... the level of member states individually. Many member states in ... the space of orphan medicinal products, the result of which ...
Breaking Medicine Technology:
(Date:12/2/2016)... ... December 02, 2016 , ... The PAINWeekEnd Regional Conference will ... Spa in Honolulu, offering local frontline clinicians the opportunity to extend their certified ... demand for supplemental training related to pain management has surged dramatically in recent ...
(Date:12/2/2016)... ... 2016 , ... Sourced from the Isbre Springs beneath the 5,000 year old ... purity of just 6 ppm TDS (Total Dissolved Solids) in addition to its excellent ... in several ShopRite and FoodTown stores in NJ and received rave comments from consumers. ...
(Date:12/2/2016)... (PRWEB) , ... December 02, 2016 , ... Yisrayl Hawkins, ... delves into how this current generation fits into Bible Prophecy. Yisrayl says this generation, ... facts pointing to this conclusion, showing how the details line up exactly with Bible ...
(Date:12/2/2016)... ... December 02, 2016 , ... Clarify Health Solutions, Inc., ... $6.0 million in an initial round of funding. The round was led by ... caregivers can receive far better care through the application of the best technologies ...
(Date:12/2/2016)... ... December 02, 2016 , ... Today CloudMine, ... connected applications, was named the best Sales Team of 2016 as part of ... made today by the Software & Information Industry Association (SIIA), the principal trade ...
Breaking Medicine News(10 mins):